Insights and discussion from the cutting edge with reference to journal articles and other research papers.
-
BrianR
- Senior Contributor
- Posts: 298
- Joined: Tue Oct 02, 2018 12:32 pm
- Location: Central Florida
Post
by BrianR »
Open access.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066743/
Alzheimer's disease drug development pipeline: 2022
Jeffrey Cummings,corresponding author, Garam Lee, Pouyan Nahed, Mina Esmail Zadeh Nojoo Kambar, Kate Zhong, Jorge Fonseca, and Kazem Taghva
Alzheimers Dement (N Y). 2022; 8(1): e12295.
Published online 2022 May 4. doi: 10.1002/trc2.12295
2022AlzheimerPipeline.png
Figure 1. Agents in clinical trials for treatment of Alzheimer's disease in 2021 (from clinicaltrials.gov as of the index date of January 5, 2021). The inner ring shows Phase 3 agents; the middle ring comprises Phase 2 agents; the outer ring presents Phase 1 therapies; agents in green areas are biologics; agents in purple are disease‐modifying small molecules; agents in orange areas are symptomatic agents addressing cognitive enhancement or behavioral and neuropsychiatric symptoms; the shape of the icon shows the population of the trial; the icon color shows the Common Alzheimer's Disease Research Ontology (CADRO)‐based class of the agent (“Other” category includes CADRO classes that have three or fewer agents in trials). Agents underlined are new to the pipeline since 2020. (Figure © J Cummings; M de la Flor, PhD, Illustrator)
You do not have the required permissions to view the files attached to this post.
-
SusanJ
- Senior Contributor
- Posts: 3058
- Joined: Wed Oct 30, 2013 7:33 am
- Location: Western Colorado
Post
by SusanJ »
Thanks for sharing. Interesting to read all the various targets of these drug trials.
The targets include amyloid; tau; apolipoprotein E (APOE)/lipids, and lipoprotein receptors; neurotransmitter receptors; neurogenesis; inflammation; oxidative stress; cell death; proteostasis/proteinopathies; metabolism and bioenergetics; vasculature; growth factors and hormones; synaptic plasticity/neuroprotection; gut‐brain axis; circadian rhythm; epigenetic regulators; multi‐target; unknown target, and other.
-
JulieAnnie
- Senior Contributor
- Posts: 75
- Joined: Mon Jul 28, 2014 10:38 am
Post
by JulieAnnie »
Great to see Montelukast in Phase 2 studies for prodromal and mild to mod dementia. Effective so far in inflammation and immunity issues.
-
JulieAnnie
- Senior Contributor
- Posts: 75
- Joined: Mon Jul 28, 2014 10:38 am
Post
by JulieAnnie »
Great to see Montelukast in Phase 2 studies for prodromal and mild to mod dementia. Effective so far in inflammation and immunity issues.